Your browser doesn't support javascript.
loading
Challenges and recommendations to increasing the use of exome sequencing and whole genome sequencing for diagnosing rare diseases in Brazil: an expert perspective.
Félix, Têmis Maria; Fischinger Moura de Souza, Carolina; Oliveira, João Bosco; Rico-Restrepo, Mariana; Zanoteli, Edmar; Zatz, Mayana; Giugliani, Roberto.
Afiliación
  • Félix TM; Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, 90,035-903, Brazil. tfelix@hcpa.edu.br.
  • Fischinger Moura de Souza C; Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, 90,035-903, Brazil.
  • Oliveira JB; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Rico-Restrepo M; Americas Health Foundation, Bogota, Colombia.
  • Zanoteli E; Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil.
  • Zatz M; Human Genome and Stem-cell Research Center, Institute of Biosciences, University of São Paulo, São Paulo, Brazil.
  • Giugliani R; Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, 90,035-903, Brazil.
Int J Equity Health ; 22(1): 11, 2023 01 13.
Article en En | MEDLINE | ID: mdl-36639662
ABSTRACT
Early diagnosis of genetic rare diseases is an unmet need in Brazil, where an estimated 10-13 million people live with these conditions. Increased use of chromosome microarray assays, exome sequencing, and whole genome sequencing as first-tier testing techniques in suitable indications can shorten the diagnostic odyssey, eliminate unnecessary tests, procedures, and treatments, and lower healthcare expenditures. A selected panel of Brazilian experts in fields related to rare diseases was provided with a series of relevant questions to address before a multi-day conference. Within this conference, each narrative was discussed and edited through numerous rounds of discussion until agreement was achieved. The widespread adoption of exome sequencing and whole genome sequencing in Brazil is limited by various factors cost and lack of funding, reimbursement, awareness and education, specialist shortages, and policy issues. To reduce the burden of rare diseases and increase early diagnosis, the Brazilian healthcare authorities/government must address the barriers to equitable access to early diagnostic methods for these conditions. Recommendations are provided, including broadening approved testing indications, increasing awareness and education efforts, increasing specialist training opportunities, and ensuring sufficient funding for genetic testing.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Enfermedades Raras Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: America do sul / Brasil Idioma: En Revista: Int J Equity Health Año: 2023 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pruebas Genéticas / Enfermedades Raras Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: America do sul / Brasil Idioma: En Revista: Int J Equity Health Año: 2023 Tipo del documento: Article País de afiliación: Brasil